PIPELINE AND R&D
PIPELINE AND R&D
Working to Bring New Medicines to Patients to Address Immediate Unmet Needs
Arvinas is dedicated to advancing comprehensive programs in oncology and neurology, including against targets that have traditionally been deemed “undruggable.”
We Create PROteolysis TArgeting Chimeras
We are engineering an expansive pipeline of PROteolysis TArgeting Chimeras, or PROTACs, designed to harness the body’s own natural protein disposal system (the ubiquitin proteasome system) to selectively and efficiently degrade and remove disease-causing proteins.
Our Research
PROTAC degraders have clear characteristics that may provide potential advantages over other modalities in oncology and neurodegenerative diseases. Arvinas is the first targeted protein degradation company to receive U.S. Food and Drug Administration (FDA) approval for a PROTAC, a type of heterobifunctional protein degrader therapy.
Pipeline
Discover more about our pipeline and clinical programs, including potential therapies for life-threatening cancers and devastating neurological disorders.
Publications
From early PROTAC discoveries to today’s expanding body of research, explore our publications capturing the evolution of targeted protein degradation.
Congress Presentations
View scientific and clinical data presented at major medical and scientific congresses, reflecting ongoing progress from our programs.
